Paggiarino Dario A. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Paggiarino Dario A.
Chief Medical Officer
Transactions
- Tax Payment
Common Stock
2024-02-09$28.80/sh−2,518$72,518→ 44,787 total - Exercise/Conversion
Common Stock
2024-02-09+4,967→ 41,472 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−2,565$73,872→ 42,222 total - Exercise/Conversion
Restricted Stock Units
2024-02-09−5,833→ 5,834 totalExercise: $0.00Exp: 2032-02-09→ Common Stock (5,833 underlying) - Exercise/Conversion
Restricted Stock Units
2024-02-09−4,967→ 0 totalExercise: $0.00Exp: 2031-02-09→ Common Stock (4,967 underlying) - Exercise/Conversion
Common Stock
2024-02-09+5,833→ 47,305 total
Footnotes (3)
- [F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
- [F2]The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
- [F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.